Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: Links to inflammation and oxidative stress

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 5, 2002, Pages 32-37

  Stenvinkel, Peter ^a   Bárány, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anaemia; Atherosclerosis; End stage renal disease; Erythropoietin; Inflammation; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CYTOKINE; ERYTHROPOIETIN; GLUTATHIONE; HEMOGLOBIN; IRON; MELATONIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE DISEASE; ANEMIA; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL DESTRUCTION; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; ERYTHROCYTE; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HEMATOPOIETIC SYSTEM; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; IRON DEFICIENCY; KIDNEY FAILURE; MALNUTRITION; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TREATMENT FAILURE;

ANEMIA; CARDIOVASCULAR DISEASES; CYTOKINES; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; TREATMENT FAILURE;

EID: 0036315869     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_5.32     Document Type: Article

References (72)

1. Inflammatory and atherosclerotic interactions in the depleted uremic patient
2. Inflammation in end-stage renal failure: Could it be treated?
3. Silent infection in clotted hemodialysis access grafts
4. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure?
5. Relationship between antibodies to peridontal pathogens and C-reactive protein (CRP) levels in hemodialysis patients
6. Serum interleukin-6 in long-term hemodialysed patients
7. Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation
8. Effects of dialyser and dialysate on the acute phase response in clinical bicarbonate dialysis
9. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis
10. Plasma C-reactive protein in hemodialysis patients: A cross-sectional and longitudinal survey
11. Clinical epidemiology of cardiovascular disease in chronic renal failure
12. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
13. Cardiovascular disease and chronic renal disease: A new paradigm
14. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
15. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
16. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients
17. Inflammation is associated with carotid atherosclerosis in dialysis patients
18. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure
19. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients
20. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: Association to chlamydia pneumoniae seropositivity
21. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA-syndrome)
22. 2-isoprostanes in patients on long-term hemodialysis
23. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure
24. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure
25. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis
26. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients
27. Albumin is the major plasma protein target of oxidant stress in uremia
28. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease
29. Atherosclerosis: An inflammatory disease
30. Infection and inflammation induce LDL oxidation in vivo
31. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment
32. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia
33. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review
34. Proinflammatory cytokines lowering erythropoietin production
35. The acute phase response and the hematopoietic system: The role of cytokines
36. Iron, infections, and anemia of inflammation
37. Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients
38. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNF-alpha
39. Advances in the anemia of chronic disease
40. Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor alpha blockade
41. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
42. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen
43. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
44. Factors determining the percentage of hypochromic red blood cells in hermodialysis patients
45. Iron metabolism and erythropoiesis after surgery
46. Iron and anemia of chronic disease
47. Regulation of iron metabolism: Translational effects mediated by iron, heme, and cytokines
48. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron
49. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium
50. IL-6-induced anaemia in rats: Possible pathogenetic implications for anemia observed in chronic inflammations
51. The impact of anemia correction on cardiovascular disease in end-stage renal disease
52. Hematocrit and the risk of cardiovascular disease the Framingham study: A 34-year follow-up
53. Mortality, malnutrition and atherosclerosis in end-stage renal disease: What is the role of interleukin-6?
54. Acute-phase inflammatory process contributes to malnutrition, anemia, and possible other abnormalities in dialysis patients
55. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
56. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin
57. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
58. Oxidation parameters in complete correction of renal anemia
59. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients
60. Effect of the hemodialysis membrane on the inflammatory reaction in vivo
61. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients
62. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy
63. Vitamin E, lipid profile, and peroxidation in hemodialysis patients
64. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): Randomised placebo-controlled trial
65. Reduction of neutrophil activation by vitamin E modified dialyzer membranes
66. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients
67. Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation
68. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis
69. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration
70. Reduced glutathione for the treatment of anemia during hemodialysis: A preliminary communication
71. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration
72. Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation